Top Healthcare Stocks
Healthcare stocks have turned much higher, with the NYSE
Healthcare Sector Index gaining 1.1% and shares of healthcare
companies in the S&P 500 adding 1.25% as a group.
In company news, BioCryst Pharmaceuticals Inc. (
) is up more than 4% at $6.76 a share after the biotechnology
company said it has selected two optimized plasma kallikrein
inhibitors to advance into preclinical development as potential
medications to prevent hereditary angioedema - a rapid swelling of
the tissue just below the surface of the skin.
The decision follows both of the new drug candidates meeting the
goals of BCRX's second-generation discovery program of improving
selectivity and bioavailability compared to BCX4161, the company
first-generation treatment for angioedema that's currently in Phase
According to the company, hereditary angioedema is a
debilitating and potentially fatal genetic condition affecting
between 1 in 10,000 to 1 in 50,000 people. In addition to painful
swelling, individuals with the malady often experience excruciating
abdominal pain, nausea and vomiting caused by swelling of the
intestinal wall while swelling of the airways in the throat can
In other sector news,
(+) GILD, (+2.7%) New Phase III trial data finds two of the
company's hepatitis C drugs treat the disease better than existing
options, with company planning to file a new drug application early
next year. Also, JPMorgan raises price target by $15 to $100.
(-) OPXA, (-10.1%) Prices offering of 4.12 mln shares at $1.70
apiece, generating about $7 mln in gross proceeds to support
continued clinical studies of the company's Tcelna drug candidate
in patients with secondary progressive multiple sclerosis.